NeoGenomics to Share Nine Abstracts at the American Association of Cancer Research (AACR) Annual Meeting 2023
NeoGenomics, Inc. (NASDAQ:NEO) has announced plans to present nine abstracts at the American Association for Cancer Research (AACR) Annual Meeting 2023, scheduled for April 14-19 in Orlando, Florida. The presentations will showcase data on the company's advanced RaDaR liquid biopsy test, designed for detecting minimal residual disease (MRD). Dr. Shashikant Kulkarni, Chief Scientific Officer, highlighted the performance comparisons of RaDaR against other MRD tests, emphasizing the firm's commitment to innovation in cancer monitoring. Each abstract covers various aspects of cancer testing, including new methodologies and technological advancements in the field. RaDaR has received FDA Breakthrough Device Designation and is validated for use across multiple cancer types, enhancing NeoGenomics' service portfolio for oncologists and pharmaceutical partners.
- NeoGenomics will showcase nine abstracts at the AACR Annual Meeting 2023, indicating active engagement in cancer research.
- RaDaR assay is highlighted for its advanced capabilities in detecting minimal residual disease, showcasing innovative cancer monitoring technology.
- The company received FDA Breakthrough Device Designation for the RaDaR assay, enhancing its market credibility.
- None.
FT. MYERS, FL / ACCESSWIRE / April 6, 2023 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology testing and global contract research services, announced today that the company and its collaborators will present a total of nine abstracts at the American Association for Cancer Research (AACR) Annual Meeting 2023 taking place April 14-19, 2023 in Orlando, Florida.
NeoGenomics, alongside collaborators, will present new data demonstrating the broad portfolio of services and available validated assays focused on tumor biology, including the use of RaDaR®, a personalized, highly-sensitive liquid biopsy sequencing test for the detection of minimal residual disease (MRD) and recurrence.
"We are especially excited to share data on RaDaR, comparing the performance of NeoGenomics' proprietary technology to other MRD tests on the market," said Dr. Shashikant Kulkarni, MS, Ph.D., MBA, FACMG, Chief Scientific Officer of NeoGenomics. "These data highlight our deep expertise in NGS profiling and our commitment to innovation in cancer monitoring to better service cancer patients and their providers."
Details of the poster presentations are outlined below, and further details can be found at AACR.org.
Title: Evaluation of a tumor informed MRD assay with contrived breast cancer samples. Abstract #3382.Monday, April 17, 1:30pm-5:00pm.
Title: Single-tube NGS profiling allows identification of molecular signature in ALL patients. Abstract #219. Sunday, April 16, 1:30pm-5:00pm.
Title: Landscape of known and novel myeloid neoplasia fusions identified by a multimodal comprehensive genomic profiling test in 789 patients. Abstract #1401. Monday, April 17, 9:00am-12:30pm.
Title: ctDNA dynamics in early stage node negative lung cancers. Abstract #3387.Monday, April 17, 1:30pm-5:00pm.
Title: Bridging the gap between targeted NGS and FISH gene-level CNV detection capabilities in hematologic malignancies.Abstract #4294.Tuesday, April 18, 9:00am-12:30pm.
Title: Single-cell immunoprofiling and spatial analysis of hormone receptor subtypes in HER2+ and HER2low breast tumors using multiplexed immunofluorescence.Abstract #4639.Tuesday, April 18, 1:30pm-5:00pm.
Title: Characterizing CD39 and CD73 cell subtypes in the tumor microenvironment using MultiOmyxTM. Abstract #4696.Tuesday, April 18, 1:30pm-5:00pm.
Title: Comprehensive analysis of natural killer cell-associated markers using MultiOmyxTM immunofluorescence assay.Abstract #4688.Tuesday, April 18, 1:30pm-5:00pm.
Title: Spatial analysis of genomic signatures on colorectal cancer pathogenesis using the GeoMx® Digital Spatial Profiler. Abstract #6788. Wednesday, April 19, 9:00am-12:30pm.
About RaDaR®
The RaDaR® assay is a personalized, tumor-informed, highly sensitive technology that tracks a set of up to 48 tumor-specific variants in cell-free DNA (cfDNA) within a cancer patient's blood plasma. Built on the proven InVision® platform, the personalized RaDaR assay has been designed to detect minimal residual disease (MRD) and recurrence following curative intent or definitive treatment, and early signs of relapse, and has been validated for clinical use in breast, colorectal, head and neck, as well as lung cancers. MRD is the trace amounts of circulating tumor DNA (ctDNA) that remain after surgery or other cancer treatment.
The RaDaR workflow leverages proprietary algorithms to both create personalized RaDaR panels for each patient and analyze results of a RaDaR test, all culminating in an exceptionally sensitive test with one of the industry's leading limit of detections (LODs) down to
The RaDaR assay is a laboratory developed test (LDT) which has been granted Breakthrough Device Designation by the US FDA for use in the detection of MRD in early-stage cancer patients and has received the CE mark for the detection of MRD and recurrence. RaDaR is also available for pharmaceutical, biotechnology companies and commercial entities in early through late-stage cancer development programs across a range of cancer types.
About MultiOmyxTM
MultiOmyx™, a proprietary multiplexed immunofluorescence (IF) technology, enables visualization and characterization of multiple biomarkers on a single FFPE tissue section. MultiOmyx protein assays utilize a pair of directly conjugated Cyanine dye-labeled (Cy3, Cy5) antibodies per round of staining. Each round of staining is imaged and followed by novel dye inactivation chemistry, enabling repeated rounds of staining and deactivation for up to 60 protein biomarkers. This unambiguous classification of diverse immune cell phenotypes and characterization of immune activation and suppression in context to tumor and stromal regions provides a comprehensive analysis of the tumor microenvironment.
About NeoGenomics, Inc.
NeoGenomics, Inc. specializes in cancer genetics testing and information services, providing one of the most comprehensive oncology-focused testing menus in the world to help physicians diagnose and treat cancer.
NeoGenomics is committed to connecting patients with life altering therapies and trials. We believe that, together, with our partners, we can help patients with cancer today and the next person diagnosed tomorrow. In carrying out these commitments, NeoGenomics adheres to all applicable state and federal data protection laws, provides transparency and choice to patients regarding the handling and use of their data through expressed authorizations and our Notice of Privacy Practices, and has invested in leading technologies to ensure the data we maintain is secured at all times.
Headquartered in Fort Myers, FL, NeoGenomics operates CAP accredited and CLIA certified laboratories in Fort Myers and Tampa, Florida; Aliso Viejo and San Diego, California; Research Triangle Park, North Carolina; Houston, Texas; Atlanta, Georgia; Nashville, Tennessee; and CAP accredited laboratories in Cambridge, UK, Rolle, Switzerland, and China. NeoGenomics serves the needs of pathologists, oncologists, academic centers, hospital systems, pharmaceutical firms, integrated service delivery networks, and managed care organizations throughout the United States, and pharmaceutical firms in Europe and Asia.
Forward Looking Statements
This press release includes forward-looking statements. These forward-looking statements generally can be identified by the use of words such as "anticipate," expect," plan," "could," "would," "may," "will," "believe," "estimate," "forecast," "goal," "project, "guidance," "plan," "potential" and other words of similar meaning, although not all forward-looking statements include these words. These forward-looking statements address various matters, including statements regarding improving operational efficiency, returning to profitable growth and its ongoing executive recruitment process. Each forward-looking statement contained in this press release is subject to a number of risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statement. Applicable risks and uncertainties include, among others, the Company's ability to identify and implement appropriate financial and operational initiatives to improve performance, to identify and recruit executive candidates, to continue gaining new customers, respond to the effects of the COVID-19 outbreak, offer new types of tests, integrate its acquisitions and otherwise implement its business plan, and the risks identified under the heading "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended December 31, 2022 filed with the SEC on February 23, 2023 as well as other information previously filed with the SEC.
We caution investors not to place undue reliance on the forward-looking statements contained in this press release. You are encouraged to read our filings with the SEC, available at www.sec.gov, for a discussion of these and other risks and uncertainties. The forward-looking statements in this press release speak only as of the date of this document (unless another date is indicated), and we undertake no obligation to update or revise any of these statements. Our business is subject to substantial risks and uncertainties, including those referenced above. Investors, potential investors, and others should give careful consideration to these risks and uncertainties.
For further information, please contact:
NeoGenomics, Inc.
Kendra Sweeney
Vice President, Investor Relations and Communications
Kendra.Sweeney@neogenomics.com
T: +1-239-877-7474
SOURCE: NeoGenomics, Inc.
View source version on accesswire.com:
https://www.accesswire.com/747898/NeoGenomics-to-Share-Nine-Abstracts-at-the-American-Association-of-Cancer-Research-AACR-Annual-Meeting-2023
FAQ
What are the key highlights from NeoGenomics' presentations at the AACR Annual Meeting 2023?
When will NeoGenomics present its abstracts at the AACR Annual Meeting 2023?
What is the significance of the RaDaR assay announced by NeoGenomics?
How does NeoGenomics' RaDaR compare to other MRD tests?
What is the main focus of the abstracts presented by NeoGenomics at the AACR Annual Meeting?
